Enlivex Therapeutics Ltd (NASDAQ:ENLV)
| 1.54 Delayed Data As of Sep 28 |  0.00 / 0.00%Today’s Change | 1.36 Today|||52-Week Range 4.92 | -60.89% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $26.6M |
Company Description
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Contact Information
Enlivex Therapeutics Ltd. 14 Einstein Street Ness Ziona Tel Aviv 7403618 |
Employees
Shareholders
| Other institutional | 1.19% |
| Mutual fund holders | 0.87% |
| Individual stakeholders | -- |
Top Executives
| Oren Hershkovitz | Chief Executive Officer |
| Veronique Amor-Baroukh | Senior Director-Operations |
| Shachar Shlosberger | Chief Financial Officer |
| Dror Mevorach | Chief Scientific & Medical Officer |
| Einat Galamidi | Vice President-Medical |
